Advertisement


Nabil F. Saba, MD, on Head and Neck Cancer: Long-Term Survival Findings With Pembrolizumab and Cabozantinib

2024 Multidisciplinary Head and Neck Cancers Symposium

Advertisement

Nabil F. Saba, MD, of Emory University, discusses study findings on 2-year survival rates in patients with recurrent metastatic head and neck squamous cell carcinoma who received pembrolizumab plus cabozantinib. The progression-free survival rate of 32% and the overall survival rate of 55% suggest a durable clinical activity of this combination therapy (Abstract 2).



Related Videos

Head and Neck Cancer

Nabil F. Saba, MD, on Preventing Radiation-Induced Mucositis in Patients With Squamous Cell Carcinoma of the Head and Neck

Nabil F. Saba, MD, of Emory University, discusses phase II study results suggesting parenteral administration of TK-90 may be an effective strategy for preventing radiation-induced oral mucositis in patients with squamous cell carcinoma of the head and neck (Abstract 10).

Head and Neck Cancer

Dan P. Zandberg, MD, on Personalized Immunotherapy for HNSCC: Progress Report

Dan P. Zandberg, MD, of UPMC Hillman Cancer Center, discusses study results showing that, although efficacy was low with both nivolumab plus ipilimumab and nivolumab plus relatlimab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC), selected patients had a numerically higher disease control rate, with a longer duration of stable disease (Abstract 4).

Head and Neck Cancer

Pooja Karukonda, MD, on Coping With Financial Toxicity in Head and Neck Cancer

Pooja Karukonda, MD, of Duke University Medical Center, discusses findings from the PaRTNer study, which addressed the large financial burden faced by patients with head and neck cancer undergoing radiotherapy, particularly older, non-White, female, and low-income patients. Dr. Karukonda discusses some ways to counter this adverse effect (Abstract 13).

Head and Neck Cancer

Evan M. Graboyes, MD, MPH, on Decreasing Delays in Adjuvant Therapy for Head and Neck Cancer

Evan M. Graboyes, MD, MPH, of the Medical University of South Carolina, discusses the results of the NDURE study, which explored the delays in starting postoperative radiation therapy in patients with head and neck cancer and ways to improve the timeliness and equity of treatment. Delays in this therapy are associated with higher recurrence and poorer survival in this population (Abstract LBA2).

Head and Neck Cancer

Evan M. Graboyes, MD, MPH, on Addressing Body Image Distress: Critical Care for Head and Neck Cancer Survivors

Evan M. Graboyes, MD, MPH, of the Medical University of South Carolina, discusses body image distress, a source of significant morbidity among head and neck cancer survivors. He recommends strategies to identify this side effect, the evidence for how best to treat, and best practices to help patients heal emotionally as well as physically.

Advertisement

Advertisement




Advertisement